RecruitingNCT05795257

Pulmonary Immune Cell-microbiome Interactions in ARDS

Pulmonary Immune Cell-microbiome Interactions in Acute Respiratory Distress Syndrome: the ILLUMINA-1 Study


Sponsor

Hvidovre University Hospital

Enrollment

40 participants

Start Date

Mar 14, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The overall aim is to compare the composition and spatial heterogeneity of the following in critically ill intensive care unit (ICU) patients: i) immune cell populations and their activation patterns, ii) the surrounding cytokine-chemokine milieu, including trans-compartmental fluxes of these mediators between the lung and bloodstream, and iii) the lung microbiome. Main hypotheses: * The immune cell population in bronchoalveolar lavage fluid (BALF) from patients with ARDS is dominated by neutrocytes, while T cells are depleted, and show evidence of hyper-activation and exhaustion * T cell hyper-activation and exhaustion is specifically compartmentalised to the lungs, and much more pronounced in moderate-to-severe than none-to-mild ARDS * Cyto- and chemokines derived from pulmonary immune cells are higher in moderate-to-severe than none-to-mild ARDS with a greater release from lungs to the bloodstream, notably of IL-6 and IL-8. * The differences in T cell profile in BALF, notably the ratio between regulatory T cells and T helper 17 cells, will change with disease severity over time, and can be explained by the presence of tI-IFN antibodies and/or a low microbial diversity of the respiratory tract with low enrichment from the oral cavity.


Eligibility

Min Age: 18 Years

Inclusion Criteria8

  • Admitted to the ICU at Hvidovre Hospital
  • Intubated within the past 72 hours
  • Moderate-to-severe ARDS according to the Berlin definition19
  • Age ≥ 18 years
  • Admitted to the ICU at Hvidovre Hospital
  • Intubated within the past 72 hours
  • None-to-mild ARDS according to the Berlin definition19
  • Age ≥ 18 years

Exclusion Criteria6

  • ARDS caused by COVID-19
  • Absolute contraindications for bronchoscopy
  • Untreated malignant arrhythmia
  • Documented or suspected intracranial hypertension (intracranial pressure ≥ > 15 mmHg)
  • One-lung ventilation
  • Severe coagulopathy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBronchoalveolar lavage

Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung


Locations(1)

Hvidovre Hospital, University of Copenhagen

Hvidovre, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05795257


Related Trials